ABUS
Arbutus Biopharma Corp
4.90$
+0.6%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +502.6% | -61.3% | -14.0% | -3.9% | -53.7% | +29.9% | +49.2% | -4.4% | -26.1% | -8.8% | -28.2% | |
| – | +58.0% | -27.9% | -2.4% | -0.1% | -27.4% | +36.1% | +25.8% | -5.9% | -12.6% | -3.6% | -25.8% | |
| – | +131.0% | -86.0% | +132.1% | -32.0% | -13.9% | +64.3% | +109.1% | -71.8% | -14.6% | +38.2% | -50.4% | |
| – | +61.6% | -28.0% | -3.1% | -1.4% | -27.1% | +35.7% | +26.0% | -5.4% | -14.2% | -2.7% | -25.4% | |
| – | -45.3% | -78.3% | +33.3% | +257.8% | -15.9% | +9.0% | -31.5% | +50.4% | +31.4% | +35.6% | -27.5% | |
| – | – | -100.0% | -100.0% | – | – | – | – | – | – | – | – | |
| – | +80.9% | +118.2% | +75.4% | -16.7% | -14.5% | -20.2% | -13.6% | -15.3% | – | – | – | |
| – | – | -85.0% | +0.0% | -7.9% | -100.0% | – | – | – | – | – | – | |
| – | – | -71.8% | -41.0% | -25.2% | – | – | – | – | – | – | – | |
| – | +445.1% | -55.7% | -25.0% | -49.4% | +18.5% | +7.1% | -0.2% | +67.1% | -34.5% | -10.5% | -47.5% | |
| – | -26.5% | +0.2% | +12.3% | -5.6% | -30.3% | +21.9% | +17.6% | +192.8% | -31.6% | -30.5% | -61.5% | |
| – | +320.9% | +7.3% | -10.5% | – | – | +14.7% | -1.8% | -2.9% | +14.2% | +13.6% | +13.3% | |
| – | +27.7% | +23.2% | -38.2% | +60.6% | -24.9% | +24.9% | +6.0% | +10.9% | -8.4% | -28.1% | -49.4% | |
| – | – | – | +0.0% | – | – | – | – | – | – | – | – | |
| – | +522.4% | -62.9% | -10.1% | +9.7% | -63.7% | +40.2% | +66.2% | -19.2% | -22.5% | -8.2% | -21.4% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +102.6% | +16.7% | +3.1% | +1.1% | +3.2% | +32.8% | +40.1% | +42.1% | +10.0% | +11.8% | +3.2% |
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.